Drug Trial Radar · NCT05844735
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
May 22, 2023
Primary completion
Oct 15, 2023
Study completion Oct 23, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age. There will be two parts: * Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo. * Part II is an open label arm consisting of participants treated with ciprofloxacin which induces mild phototoxicity and serves as a positive control.
Conditions
- Rheumatoid Arthritis
Interventions
SAR441566Drug
Tablet
PlaceboDrug
Tablet
CiprofloxacinDrug
Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1Time frame: On-drug Day 8
- Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 1Time frame: On-drug Day 8
- Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 1Time frame: On-drug Day 9
- Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 2Time frame: On-drug Day 8
- Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 2Time frame: On-drug Day 8
- Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 2Time frame: On-drug Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TKL Research, Inc. Site Number : 8400001
Fair Lawn, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.